Tag: Iksuda Therapeutics
11th World ADC Awards 2024: Celebrating a Decade of Excellence
Earlier this week, during the 15th World ADC in San Diego, CA, the 11th World ADC Awards reunited both newcomers and leaders of the...
Iksuda Therapeutics Closes Financing Round with Mirae Asset Capital, Celltrion and...
A developer of a new generation of antibody-drug conjugates, Iksuda Therapeutics, has completed a US $47 million (UK £34 million) financing round. The financing...
LegoChem Biosciences and Iksuda Sign Multi-Target Research Collaboration and License Agreement
In a statement, South Korean LegoChen Biosciences and UK's Iksuda Therapeutics confirmed that the companies have entered into a multi-target research collaboration and license...
Femtogenix Signs License Agreement with Iksuda Therapeutics
Iksuda Therapeutics, formerly known as Glythera, confirmed that it has signed a licensing agreement with Femtogenix. The agreement gives Iksuda access to Femtogenix’s therapeutic,...
